While immunotherapy, such as immune checkpoint inhibition monotherapy (e.g., antibodies against PD-1 or PD-L1), has dramatically changed the therapeutic concepts of different cancer types, especially those with mismatch repair deficiency (2), the benefit for ovarian cancer patients with an objective response rate of approximately 10% was found to be rather modest (3–6). The gene discussed is CD274; the disease is ovarian cancer.